Lantibiotic biosynthetic gene clusters from A....

Details Lantibiotic biosynthetic gene clusters from A.... Lantibiotic biosynthetic gene clusters from A....

2011-08-02

2011-08-02

Ha, Julie (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S001100, C514S002400, C514S002600, C514S002700, C530S317000

Reexamination Certificate

active

07989416

ABSTRACT:
Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.

REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 5112806 (1992-05-01), Chatterjee et al.
patent: 5304540 (1994-04-01), Blackburn et al.
patent: 5667991 (1997-09-01), Koller et al.
patent: 5683675 (1997-11-01), Vedia et al.
patent: 5763395 (1998-06-01), Blackburn et al.
patent: 5958873 (1999-09-01), Sakr et al.
patent: 5985823 (1999-11-01), Goldstein
patent: 6022851 (2000-02-01), Vertesy et al.
patent: 6569830 (2003-05-01), Climo et al.
patent: 7122514 (2006-10-01), Climo et al.
patent: 2010/0168410 (2010-07-01), Cade et al.
patent: 197 45 583 (1999-04-01), None
patent: 0195359 (1986-09-01), None
patent: 0572942 (1993-12-01), None
patent: 0700998 (1996-03-01), None
patent: 1646646 (2007-03-01), None
patent: WO 91/07949 (1991-06-01), None
patent: WO 91/11172 (1991-08-01), None
patent: WO 94/02518 (1994-02-01), None
patent: WO 97/00694 (1997-01-01), None
patent: WO 98/55148 (1998-12-01), None
patent: WO 02/00196 (2002-01-01), None
patent: WO 02/088367 (2002-11-01), None
patent: WO 02/103010 (2002-12-01), None
patent: WO 03/099862 (2003-12-01), None
patent: WO 2004/033706 (2004-04-01), None
patent: WO 2005/093069 (2005-10-01), None
patent: WO 2006/080920 (2006-08-01), None
patent: WO 2007/036706 (2007-04-01), None
patent: WO 2007/083112 (2007-07-01), None
patent: WO 2008/151434 (2008-12-01), None
patent: WO 2009/010763 (2009-01-01), None
patent: WO 2009/010765 (2009-01-01), None
patent: WO 2010/058238 (2010-05-01), None
patent: WO 2010/082018 (2010-07-01), None
patent: WO 2010/082019 (2010-07-01), None
patent: WO 2010/092019 (2010-07-01), None
patent: WO 2010/089544 (2010-08-01), None
Definition of moiety, from http://dictionary.reference.com/browse/moiety, pp. 1-3. Accessed Aug. 26, 2010.
Rudinger J, “Characteristics of the amino acids as components of a peptide hormone sequence,” Peptide Hormones, JA Parsons Edition, University Park Press, Jun. 1976, pp. 1-7.
“Designing Custom Peptides,” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Schinzel R, Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” FEBS, Jul. 1991, 286(1,2): 125-128.
Berendsen HCJ, “A Glimpse of the Holy Grail?” Science, 1998, 282: 642-643.
Voet D, Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Ngo JT, Marks J, Karplus M, “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. and S. Le Grand Edition, 1994, pp. 491-495.
Bradley CM, Barrick D, “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol., 2002, 324: 373-386.
European Search Report issued in European Patent Application No. EP 10 00 0424 (Apr. 1, 2010).
European Examination issued in European Patent Application No. 07 704 921.1 (Apr. 4, 2010).
International Search Report and Written Opinion in PCT/GB2010/000043 (Mar. 29, 2010).
Widdick et al., “Cloning and engineering of the cinnamycin biosynthetic gene cluster fromStreptomyces cinnamoneus cinnamoneusDSM 40005”, PNAS, 100(7):4316-4321 (Apr. 1, 2003).
Arioli et al. “Gardimycin, a new anitbiotic fromActinoplanes: III. Biological properties” The Journal of Antibiotics 29(5):511-515 (1976).
Berge et al. “Pharmaceutical salts” Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
Bierbaum et al. “Cloning, sequencing and production of the lantibiotic mersacidin” FEMS Microbiology Letters 127:121-126 (1995).
Bierman et al. “Plasmid cloning vectors for the conjugal transfer of DNA fromEscherichia colitoStreptomycesspp.” Gene 116(1): 43-49 (1992).
Britton et al. “Genome-Wide Analysis of the Stationary-Phase Sigma Factor (Sigma-H) Regulon ofBacillus subtilis” Journal of Bacteriology 184(17):4881-4890 (2002).
Castiglione et al. “A novel lantibiotic acting on bacterial cell wall synthesis produced by uncommon actinomycetePlanomonosporasp.” Biochemistry 46:5884-5895 (2007).
Chatterjee et al. “Biosynthesis and Mode of Action of Lantibiotics” Chem. Rev. 105:633-683 (2005).
Coronelli et al. “Gardimycin, A New Antibiotic From Actinoplanes: II. Isolation and preliminary characterization” Journal of Antibiotics 29(5):507-510 (1976).
Cotter et al. “Bacterial lantibiotics: strategies to improve therapeutic potential” Current Protein Peptide Science 6(1):61-75 (2005).
Dabard et al. “Ruminococcin A, a new lantibiotic produced by aRuminococcus gnavusstrain isolated from human feces” Appl. Environ. Microbiol. 67:4111-4118 (2001).
Dawson “Lantibiotics as antimicrobial agents” Expert Opinion on Therapeutic Patents, Informa Healthcare, GB, 17(4):365-369 (2007).
Dower et al. “High efficiency transformation ofE. coliby high voltage electroporation” Nucleic Acids Research 16(13):6127-6145 (1988).
Fleisher et al. “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs” Advanced Drug Delivery Reviews 19(2):115-130 (1996).
Flett et al. “High efficiency intergeneric conjugal transfer of plasmid DNA fromEscherichia colito methyl DNA-restricting Streptomycetes” FEMS Microbiology Letters 155(2): 223-229 (1997).
Fukase et al. “Synthetic study of peptide antibiotic nisin. V. Total synthesis of nisin” Bull. Chem. Soc. Jpn. 65:2227-2240 (1992).
Fumi et al. “Rifaximin treatment for symptoms of irritable bowel syndrome” The Annals of Pharmacotherapy 42:408-412 (2008).
Gardiner et al. “Fate of the Two-Component Lantibiotic Lacticin 3147 in the Gastrointestinal Tract” Applied and Environmental Microbiology 73(21):7103-7109 (2007).
Gravesen et al. “pbp2229-Mediated nisin resistance mechanism inListeria monocytogenesconfers cross-protection to class IIa bacteriocins and affects virulence gene expression” Applied and Environmental Microbiology 70(3): 1669-1679 (2004).
Guder et al. “Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity” Applied and Environmental Microbiology 68(1):106-113 (2002).
Guiotto et al. “PEGylation of the antimicrobial peptide nisin A: problems and perspectives” I1 Farmaco 58(1):45-50 (2003).
Gust et al. “PCR-targeted Streptomyces gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin” PNAS 100(4): 1541-1546 (2003).
Gust et al. “λ Red-mediated genetic manipulation of antibiotic-producing Streptomyces” Advances in Applied Microbiology 54:107-128 (2004).
Heinzelmann et al. “A glutamate mutase is involved in the biosynthesis of the lipopeptide antibiotic friulimicin inActinoplanes friuliensis” Antimicrobial Agents and Chemotherapy 47(2): 447-457 (2003).
Hilger et al. “Differential binding of IgG and IgA antibodies to antigenic determinants of bovine serum albumin” Clin. Exp. Immunol. 123:387-394 (2001).
Holtsmark, et al. “Purification, Characterization, and Gene Sequence of Michiganin A, an Actagardine-Like Lantibiotic Produced by the Tomato PathogenClavibacter michiganensissubsp.michiganensis” Applied and Environmental Microbiology 72(9):5814-5821 (2006).
Kettenring et al. “Sequence determination of actagardine, a novel lantibiotic, by homonuclear 2D NMR spectroscopy” J. Antibiot. 43(9):1082-1088 (1990).
Lonetto et al. “The sigma 70 family: sequence conservation and evolutionary relationships” Journal of Bacteriology 174(12): 3843-3849 (1992).
Louie et al. “A phase 2 st

Affiliated with

Also associated with

Rating

Lantibiotic biosynthetic gene clusters from A.... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lantibiotic biosynthetic gene clusters from A...., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lantibiotic biosynthetic gene clusters from A.... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2749106